Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy

Cancer

Volumn 91, Issue 6, 2001, Pages 1079-1089

  Pierga, Jean Yves ^a   Asselain, Bernard ^a   Jouve, Michel ^a   Diéras, Véronique ^a   Carton, Mathieu ^a   Laurence, Valérie ^a   Girre, Véronique ^a   Beuzeboc, Philippe ^a   Palangié, Thao ^a   Dorval, Thierry ^a   Pouillart, Pierre ^a  

^a INSTITUT CURIE   (France)

Author keywords

Adjuvant chemotherapy; Metastatic breast carcinoma; Prognostic factor

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DOXORUBICIN; FLUOROURACIL; LACTATE DEHYDROGENASE; MEDROXYPROGESTERONE; METHOTREXATE; METHYLPREDNISOLONE; MITOMYCIN C; TAMOXIFEN; TENIPOSIDE; VINCRISTINE; VINDESINE;

ADULT; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; HUMAN TISSUE; LIVER DISEASE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HEALTH STATUS; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0035868615     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010315)91:6<1079::AID-CNCR1103>3.0.CO;2-S     Document Type: Article

References (48)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
2. Polychemotherapy for early breast cancer: An overview of the randomised trials
3. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women
4. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy
5. Classification of patients with disseminated cancer of the breast
6. Prognostic factors in metastatic breast cancer treated with combination chemotherapy
7. Prognostic factors in metastatic breast cancer
8. Multivariate analysis of prognostic factors in metastatic breast cancer
9. Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients
10. Prognostic factors in recurrent breast cancer: Relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading
11. Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: A prospective Eastern Cooperative Oncology Group study
12. Significance of relapse after adjuvant treatment with combination chemotherapy or 5-fluorouracil alone in high-risk breast cancer
13. Effects of adjuvant chemotherapy on the natural history and likelihood of therapeutic efficacy in advanced breast cancer patients: A critical literature review
14. Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer
15. The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer
16. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support
17. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of firstline cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer
18. Disseminated breast carcinoma, study of activity of immunotherapy with BCG and duration of the phase of intensive chemotherapy. Results of a randomized trial
19. Advanced breast cancer: Controlled trial of chemotherapies with and without hormones
20. Disseminated breast cancer: Sequential administration of tamoxifen and medroxyprogesterone acetate. Results of a controlled trial
21. Metastatic breast cancer. Modality of association of chemotherapy and hormonotherapy. Results of a controlled trial
22. Metastatic breast cancer. Chemotherapy with adriamycin, vindesine, cyclophosphamide and 5FU. Interest of continuous 5FU infusion
23. Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90)
24. Assessment of response to therapy in advanced breast cancer: A project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland
25. Regression models and life tables
26. Nonparametric estimation from incomplete observations
27. Evaluation of survival data and two new rank order statistics arising in its consideration
28. A generalized Kruskal-Wallis test for comparing k samples subject to unequal patterns of censorship
29. Effect of systemic adjuvant treatment on first sites of breast cancer relapse
30. Significance of axillary lymph node metastasis in primary breast cancer
31. Prior adjuvant chemotherapy adversely affects the outcome of metastatic breast cancer patients
32. Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy
33. Sequential assessment of MDR pheno-type and mesurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy
34. Detection and clinical importance of micrometastatic disease
35. Effect of a National Cancer Institute clinical alert on breast cancer practice patterns
36. Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy
37. Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer
38. Steroid-hormone receptors and survival after first relapse in breast cancer
39. The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast
40. Oestrogen receptors in primary and advanced breast cancer: An eight year review of 704 cases
41. Oestrogen-receptor status and sites of metastases in breast cancer
42. Construction and validation of a practical prognostic index for patients with metastatic breast cancer
43. Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer. A prospective study with more than 10 years of follow up
44. Survival outcome from a cohort of 953 metastatic breast cancer (MBC) patients referred and treated in a single institution during the last 40 years
45. Clinical course of breast cancer patients with liver metastases
46. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer
47. A phase III trial comparing doxorubicin (A) and Docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC
48. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with nodepositive primary breast cancer (BC)